See more : EcoPlus Inc. (ECPL) Income Statement Analysis – Financial Results
Complete financial analysis of Biocept, Inc. (BIOC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biocept, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Microwave Filter Company, Inc. (MFCO) Income Statement Analysis – Financial Results
- Yao I Fabric Co., Ltd. (4430.TWO) Income Statement Analysis – Financial Results
- Jungfraubahn Holding AG (0QNG.L) Income Statement Analysis – Financial Results
- Acorda Therapeutics, Inc. (ACOR) Income Statement Analysis – Financial Results
- Texaf S.A. (TEXF.BR) Income Statement Analysis – Financial Results
Biocept, Inc. (BIOC)
About Biocept, Inc.
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.86M | 61.25M | 27.46M | 5.53M | 3.25M | 5.07M | 3.22M | 609.91K | 133.42K | 134.25K | 109.29K | 1.05K |
| Cost of Revenue | 28.44M | 37.76M | 21.34M | 10.98M | 10.05M | 9.35M | 6.92M | 4.60M | 2.17M | 2.33M | 1.20M | 17.32K |
| Gross Profit | -2.58M | 23.49M | 6.12M | -5.45M | -6.80M | -4.28M | -3.70M | -3.99M | -2.04M | -2.20M | -1.09M | -16.27K |
| Gross Profit Ratio | -9.99% | 38.34% | 22.30% | -98.56% | -209.26% | -84.37% | -114.70% | -653.58% | -1,526.91% | -1,635.56% | -999.56% | -1,546.58% |
| Research & Development | 6.16M | 4.96M | 5.22M | 4.70M | 4.47M | 3.36M | 2.71M | 2.86M | 4.50M | 3.09M | 6.56M | 8.85M |
| General & Administrative | 16.11M | 12.61M | 9.97M | 6.97M | 7.07M | 7.19M | 6.56M | 5.69M | 5.20M | 2.51M | 2.06M | 2.73M |
| Selling & Marketing | 7.13M | 8.32M | 6.40M | 5.94M | 5.91M | 6.34M | 5.05M | 3.88M | 2.14M | 148.90K | 785.32K | 672.93K |
| SG&A | 23.24M | 20.93M | 16.37M | 12.91M | 12.99M | 13.53M | 11.61M | 9.57M | 7.34M | 2.66M | 2.85M | 3.40M |
| Other Expenses | 0.00 | 0.00 | 0.00 | -1.83M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 29.40M | 25.89M | 21.59M | 17.61M | 17.46M | 16.90M | 14.33M | 12.42M | 11.84M | 5.75M | 9.41M | 12.25M |
| Cost & Expenses | 57.84M | 63.66M | 42.93M | 28.59M | 27.51M | 26.24M | 21.25M | 17.02M | 14.01M | 8.08M | 10.61M | 12.27M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 316.00K | 290.00K | 2.34M | 2.08M | 310.98K | 0.00 | 0.00 | 0.00 | 0.00 | 2.07M | 0.00 | 0.00 |
| Depreciation & Amortization | 1.66M | 2.64M | 1.00M | 773.31K | 800.91K | 575.72K | 322.03K | 261.41K | 251.20K | 266.55K | 365.57K | 369.31K |
| EBITDA | -30.33M | -2.41M | -15.47M | -23.06M | -24.26M | -21.17M | -18.03M | -16.41M | -13.87M | -7.68M | -10.57M | -12.24M |
| EBITDA Ratio | -117.29% | -3.93% | -56.33% | -417.05% | -746.35% | -417.76% | -559.25% | -2,690.70% | -10,399.07% | -5,719.30% | -9,671.01% | -1,163,859.41% |
| Operating Income | -31.98M | -2.41M | -15.47M | -23.06M | -24.26M | -21.17M | -18.03M | -16.41M | -13.87M | -7.94M | -10.50M | -12.27M |
| Operating Income Ratio | -123.69% | -3.93% | -56.33% | -417.05% | -746.35% | -417.76% | -559.25% | -2,690.70% | -10,399.07% | -5,917.86% | -9,610.37% | -1,166,444.49% |
| Total Other Income/Expenses | -229.00K | -290.00K | -2.34M | -2.08M | -310.98K | -431.41K | -372.23K | -537.12K | -1.99M | -1.29M | -1.76M | -1.36M |
| Income Before Tax | -32.21M | -2.70M | -17.81M | -25.14M | -24.57M | -21.61M | -18.40M | -16.95M | -15.86M | -9.23M | -12.26M | -13.63M |
| Income Before Tax Ratio | -124.57% | -4.41% | -64.84% | -454.69% | -755.92% | -426.27% | -570.79% | -2,778.76% | -11,891.12% | -6,877.26% | -11,216.80% | -1,295,483.46% |
| Income Tax Expense | -125.00K | 125.00K | -764.58K | -523.33K | 1.89K | 7.62K | 2.05K | 1.61K | 1.51K | 800.00 | 800.00 | 800.00 |
| Net Income | -32.09M | -2.82M | -17.04M | -24.61M | -24.57M | -21.61M | -18.40M | -16.95M | -15.87M | -9.23M | -12.26M | -13.63M |
| Net Income Ratio | -124.09% | -4.61% | -62.06% | -445.23% | -755.98% | -426.42% | -570.86% | -2,779.03% | -11,892.25% | -6,877.86% | -11,217.53% | -1,295,559.51% |
| EPS | -56.78 | -5.73 | -43.16 | -357.54 | -2.63K | -7.07K | -17.29K | -23.28K | -96.74K | -55.29K | -73.41K | -81.61K |
| EPS Diluted | -56.78 | -5.73 | -43.16 | -357.41 | -2.63K | -7.07K | -17.29K | -23.28K | -96.74K | -55.29K | -73.41K | -81.61K |
| Weighted Avg Shares Out | 565.13K | 492.53K | 394.84K | 68.85K | 9.33K | 3.06K | 1.06K | 728.00 | 164.00 | 167.00 | 167.00 | 167.00 |
| Weighted Avg Shares Out (Dil) | 565.13K | 492.53K | 394.84K | 68.87K | 9.33K | 3.06K | 1.06K | 728.00 | 164.00 | 167.00 | 167.00 | 167.00 |
Biocept says demand for its COVID-19 RT-PCR testing increases in 2022 amid Omicron variant surge
Biocept Reports an Increase in COVID-19 RT-PCR Testing Volume with Spread of the Omicron Variant
Has Biocept, Inc. (BIOC) Outpaced Other Medical Stocks This Year?
Biocept says its CNSide assay identified HER2 and other tumor alterations in cerebrospinal fluid of patients with breast cancer and leptomeningeal disease
Biocept's CNSide Cerebrospinal Fluid Assay Identifies Actionable HER2 Mutations in Patients with Breast Cancer that has Metastasized to the Brain
Quest Diagnostics Now Offers Biocept's Liquid Biopsy Test for Lung Cancer, Expanding its Menu of Advanced Cancer Diagnostics
Biocept launches single test for COVID-19 and Influenza as cases rise during flu season
Biocept Launches Combined COVID-19 and Influenza Test to Provide Answers During Peak Flu Season
CORRECTING and REPLACING Biocept's CNSide Cerebrospinal Fluid Assay Aids in Monitoring Treatment Response and Detects Actionable Biomarkers in Patients with Metastatic Breast Cancer
Biocept to present latest findings on CNSide cerebrospinal fluid assay and its use in treating breast cancer complications at Society for Neuro-Oncology annual meeting
Source: https://incomestatements.info
Category: Stock Reports